Eitan Pe’er1
(1)
Gyneco-Endocrinology Unit, Rambam Health Campus, Technion School of Medicine, Haifa, Israel
Eitan Pe’er
Email: eitanpeer@gmail.com
1 Introduction
Progesterone plays a crucial role in the development of the breast alveolar tissue, and ductal branching.
When pregnancy takes place, the placenta produces progesterone in increasing amounts to support the pregnancy and prepare the breast for lactation. As a woman ages, the amount of progesterone produced by the corpus luteum slowly decreases. The clinical results are shortening of the luteal phase, with concomitant shortening of the menstrual cycle and increasing incidence of premenstrual syndrome (PMS) [1].
Progesterone and progestogens are have many uses in gynecology:- including treatment of menstrual disorders, combined oral contraception, and progesterone only contraception, hormone releasing IUD’s (LNG-IUS) PMS, prevention of premature uterine contractions, hormonal support of implantation after assisted reproduction, prevention of miscarrage etc [2].
The use of progestogens in menopausal hormone therapy (MHT) gained popularity after Ziel and Finkle’s [3] report showing that treatment with estrogen alone causes endometrial hyperplasia and cancer. However, these effects were completely counteracted by the addition of progestone to the estrogen replacement therapy. As hormone replacement therapy (HRT gained popularity, many synthetic forms of progestogen were introduced and are commonly used nowadays). These synthetic progestogens differ from one another in their structure, receptor affinity, metabolism and biological effects as described in other chapters.
The Women’s Health Initiative (WHI) study examined post menopausal hormone replacement therapy with conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA). The study was stopped prematurely because of an increased risk of breast cancer (HR-1.26). However in women treated with CEE alone where MPA was not added due to previous hysterectomy there was no increase in the breast cancer risk compared to placebo (HR-0.80) [4]. The lower incidence of breast cancer was also seen in the WHI extended follow-up up study of 11.8 years [5]. Since the publication of the WHI trial there has been additional epidemiological data, all confirming that the addition of progestins to estrogen increases the risk of breast cancer when compared to estrogen treatment alone. Jick et al. [6] reported a case control study of 33,000 women. The reported odds ratio was not significant for developing invasive breast cancer in women using estrogen alone (OR 0.96 95 % CI 0.88–1.06) versus a significantly increased odds ratio of 1.44 (95 % CI 1.31–1.58); for those women using estrogen and progestogen. A meta-analysis [7] of four randomized trials published up to 2006, found a non significant RR of 0.79 (95 % CI = 0.61–1.02) for invasive breast cancer in estrogen only users and a statistically significant increased RR of 1.24 (95 % CI = 1.03–1.50) with estrogen and progestogen. Epidemiological studies have reported a non significant RR of 1.18 (95 % CI = 1.01–1.38) in estrogen only users, and a significantly increased RR of 1.70 (95 % CI = 1.36–2.17) with the use of estrogen plus progestin [7]. In view of the accumulated data cited above, some of the original authors of the WHI report have reiterated their original conclusions, stating that the use of “estrogen-alone treatment” reduces the breast cancer risk and does not substantially interfere with breast cancer detection by mammography [8].
As the molecular understanding of hormonal actions has expanded, with increased clarification of the different modes of action with specific co-activators and co-regulators when attached to their specific receptors, it became clear that not all the progestogens are the same. The French E3N Study comprised of 80,377 postmenopausal women followed up for more than 8 years, using different regimens of hormone therapy. The use of transdermal estrogen with a dehydroprogesterone combination was not associated with an increased risk of breast cancer. All other forms of estrogen progestogen combinations showed an increased breast cancer risk [9].
From a practical and clinical point of view, each progestogen has its own unique biological profile which may, or may not, be shared with other progestogens. The different actions of progestogens are fully described in Chap. 2on the Pharmacology of the progestogens.
The effect of the normal menstrual cycle on the breast is well known. At the mid-luteal phase, corresponding to the peak level of luteal progesterone, mammary epithelial DNA synthesis and mitosis is at its highest. Hence, progesterone can be clearly seen to have a proliferative effect on the breast epithelium.
During pregnancy, placentally derived high levels of progesterone induce further lobular-alveolar development of the breast, in preparation for lactation. However, if high doses of progesterone are administered before breast surgery, there is less mitotic activity than after treatment with estrogen and progesterone. Therefore, estrogen and progesterone seem to act synergistically in the breast (and not antagonistically as in the endometrium). It has been shown that a single pulse of progesterone has growth stimulatory effect on cultured breast cells, but subsequent effects of further pulses of progesterone are growth inhibitors. There is an arrest of further cell cycles in the late G1stage. Several factors, such as cyclins D1 D3, decrease, or become inactivated by hypophosphorylation and inhibitory factors (such as kinase inhibitors p21, p27) which are induced by progestins. Hence, there is failure to induce further mitosis by frequent progesterone pulses [10].
2 Progesterone Receptors
The progesterone receptor is a single gene expressed in two isoforms: PR-A (94 kDa) and PR-B (116 kDa). There are homodimers (A-A), (B-B) and heterodimers (A-B) occurring naturally, in different proportions in different target tissues in the female body. They exhibit distinct transcriptional regulatory functions targeting various subsets of genes [11]. The inactivated receptor is activated by hormone (ligand) binding. This hormone-receptor complex translocates to the nucleus where it binds to specific DNA sequences in the promoter regions of target genes to activate gene expression. Alternatively, the expression of specific target genes can be repressed through interaction with various transcriptional factors such as nuclear factor kappa β (NFkβ). Consequently, the clinical significance of activation of the receptor is critically dependent on the transcriptional co-activators and repressors [12]. PR-A is mainly located in the nucleus. This receptor is required for uterine development. PR-B, which is essential for breast development, continuously shuttles between nuclear and cytoplasmatic compartments [13, 14]. Both receptors are co-expressed in the same tissues usually in equal ratios. In humans, normal mammary gland function may rely upon the balanced expression of the two PR isoforms. In breast cancer cells, however this ratio is often altered. An imbalance between the two isoforms appears to be linked to different cancerous phenotypes in the breast [15]. PR-A receptors are more stable and less active. PR-B receptors undergo extensive cross-talk with mitogenic protein kinases and are therefore heavily phosphorylated (more often via action of growth factors) [16]. The PRs can be phosphorylated (and therefore modified) after ligand treatment in response to local growth factors. Mitogenic protein kinase activity is very high in a cancerous environment. They have been shown to persistently phosphorylate, and thus modify PRs action, even in the absence of a ligand. This causes an inappropriate activation of PRs affecting PR modifying binding partners. Therefore PR action differs in normal breast tissue compared to neoplastic breast tissue. Additionally, the presence or absence of estrogen has a significant modifying effect on the PR. These effects are also organ specific, proliferating in the breast inhibitory in the endometrium. In summary, the PR has complex and versatile actions which are:—(1) different in normal and neoplastic tissue. (2) Tissue specific. (3) have different biological clinical actions regarding PR-A and PR-B. (4) May be ER dependent or ER independent. (5) Can act independently without binding ligand (progesterone). (6) different and specific for each progestogen. (7) different if given un a continuous or cyclic fashion. The above effects clearly indicate the varied effects that progestogens have on breast cancer cells biology, but the mechanisms are still not fully elucidated [17].
3 Breast Cancer: The Progesterone Effect
Breast cancer is the most common tumor in women. The life time risk of developing breast cancer is 12 %. Most of the neoplasms present after the menopause and the incidence rises sharply with age. Approximately 5–8 % of tumors arise due to a hereditary predisposition e:g, BRCA-1 mutation. Most breast cancers are initially hormone dependent with estrogen playing a crucial role in development and progression. Breast cancer may develop very slowly having a mean doubling time of 90 days. After a period that may last several years, many breast cancers become hormone independent [18]. Hormone independence may be due a mutation in the estrogen receptor.
Breast cancers are subdivided into two major subtypes:- 1.) Luminal, estrogen receptor positive (ER+), progesterone receptor positive (PR+), cytokeratin 18 positive (CK18+). These tumors make up approximately 80 % of all breast cancers. 2.) Basal ER-, PR-, CK5+. These tumors have a much worse clinical prognosis [19, 20]. In the human breast, normal stem cells are found. They can be defined by expression of epithelial specific antigen (ESA) and α6-integrin. Some believe that ER+ /PR+ luminal cancer cells arise from distinct ER+/PR+ stem cells [21]. However, in recent years it was discovered that in solid ER+/PR+ experimental tumors, CK5+ cells persist that are ER-/PR- stem cells that are actually up regulated by progestins [22]. These colonies, though small in size (up to 100 or less cells) expand and can differentiate into the more common ER+/PR+/CK5-,tumors. Approximately, 2 % of cells in these receptor positive breast cancers retain the ER-/PR-/CK5- stem like signature. [23]. Treatment of ER-/PR-/CK5+ colonies with progesterone, but not with estrogen, leads to an increase in the ER-/PR-/CK5+ stem cell subpopulation from 1 to 2 % to over 20 %. MPA (medroxy-progesterone acetate) has been found to have a more significant effect than other progestins. This increase is independent of estrogen. Hence, it seems that tumor cells can regress from a differentiated state to a more stem-like state, in response to progestins. [24]. Reactivation of the CK5+ cells (with strong CK18 expression, proving it to be of luminal origin) by 24 h of MPA exposure is usually more pronounced in the younger recently formed tumors.
It can be thus concluded that progestins, acting via their progesterone receptor affect the more abundant ER+/PR+/CK5 differentiated cells to reactivate ER-/PR-/CK5+ stem cells. It seems that progestogens have the ability to restore cancer stem cell like properties to some ER+/PR+ breast cancer cells. Only after this effect takes place, can estrogen resume growth and proliferation of the stem cells to expand ER+/PR+/CK5- breast tumors.
4 Local Production and Action of Progestins
The pharmacological properties of progestogens vary according to the parent molecule from which they are derived (testosterone, progesterone, aldosterone etc.) This, together with their ability to activate or deactivate related glucocorticoid receptors, mineralocorticoid receptors and androgen receptors is the reason for the different biological activities specific to each progestogen [25]. The enzyme, 5α-reductase, converts progesterone to 5α-pregnanes (e.g. 5α-dihydro-progesterone= 5α-P). 5α-reductase is highly expressed in cancerous cells but not in normal breast cells. 5α-P which is mainly produced by the cancerous cells stimulates cell proliferation and metastasis via activation of the MAP-kinase pathway [26]. In contrast, in normal breast cells, 5α-reductase activity is low. However, other enzymes, namely 3α-hydroxysteroid oxidoreductase and 20α-hydroxysteroid oxidoreductase metabolize progesterone to 3α-dihydroprogesterone (3α-HP) and 20α-dihydroprogesterone (20α-HP). These metabolites exert an anti-mitogenic effect and increase apoptosis and cell adhesion [27]. In tumor tissue, the concentration of mitogenic 5α-pregnane was 14 times that of the anti mitogenic 3α-HP. In contrast, in the adjacent normal breast cells, the concentration of antimitogenic 3α-HP was more than three times that of the mitogenic 5α-pregnane [26]. In view of the fact that 5α-P stimulates cell proliferation and metastasis, while 3α-HP and 20α-HP exert an antimitogenic effect, increasing apoptosis and cell adhesion, treatment with progesterone may stimulate cell growth only in the presence of malignant breast tissue [28].
Both ER/PR positive and ER/PR negative breast tumors are able to convert progesterone to 3α-HP. Specific high affinity membrane receptors exists for both 5α-P and 3α-HP. These receptors are completely distinct not only from each other but also from known ER, PR, AR and corticosteroid receptors [26]. Levels of 5α-P receptors are up-regulated by 5α-P and estradiol, and down-regulated by 3α-HP in both ER/PR positive and negative tumor cells [28]. 5α-P and 3α-HP have opposing effects on initiation and growth of ER/PR negative human breast tumors. These metabolites, which are independly produced by breast cancer cells, underscore the importance of the microenvironment in regulating expression of receptors, adhesion molecules, growth promoters and inhibitors within the breast cancer cells. 3α-HP maintains normal breast tissue. It inhibits proliferation, tumor initiation and tumor growth. 5α-P has exactly the opposite effects. It induces proliferation, tumor growth and detachment and reduces apoptosis.
5 Progesterone and Migration of Breast Cancer Cells
Death from breast cancer is usually due to invasion and metastasis to distant target organs (e.g. brain, bone lungs). Progesterone and progestins stimulate breast cancer migration and invasion [29]. The migration and invasion of cancer cells involve complex mechanisms. The first step is reorganization of the cells actin/myosin cytoskeleton. This reorganization enables the cells to develop membrane protrusion (called filopodia and lamellipodia). These protrusions are involved in the cell’s ability to detach itself from the main tumor body and, to enter lymphatic vessels and migrate. There are several 17β-estradiol up-regulating families of actin-binding protein which leads to this phenomena [30]. Studies comparing the specific effect of different synthetic progestins have demonstrated their individual and different effect on PR+ breast cancer cell migration and invasion in vitro. This activation is mediated in synergy with the activation of the actin-binding protein moesin to increase the formation of membranous structures. These specialized structures interact with the extra cellular matrix of nearby cells, allowing locomotion of the breast cells. [31]. It has been suggested that an in vitro “invasion index” for the effect of specific progestins on breast cancer cells lines incubated in vitro, with the addition of each progestin, with or without estrogen in the media can indicate the different and variable effects of progestins [32].
6 Protease Activated Receptors and Progesterone
Focal Adhesion Kinase (FAK) is a protein that belongs to the family of cytoplasmic tyrosine kinases. When activated, FAK associates with FA (focal adhesion) proteins allowing autophosphorylation at the docking site of the cells. Mature FA complexes, together with phosphorylated FAK recruit other proteins to allow cell detachment [33]. The protease-activated receptors (PARs) are a family of four vascular receptors that respond to local changes in the proteolytic environment. These receptors are activated by thrombin. PARs are important in tissue repair and response to injuries [34]. In tumor cells, PAR2 is activated by factor VIIa-tissue factor (TF), regulating proangiogenic growth factor expression. TF is strongly induced by progesterone in breast cancer cell lines [35].
The ability of progestins to regulate PAR expression appears to be cell specific (endometrium, cervix, vascular vessels, breast etc.). This action is also progestin’s specific; levonorgestrel down regulates PAR1 in the endometrium, MPA up regulates PAR1expresion in vascular endothelial cells etc. [33]. Over expression of PAR1 is a feature of many metastatic cancers. These cancers are more invasive in vitro [34]. It has been demonstrated that progesterone regulates PAR1 at the mRNA and protein levels [35]. This regulation is dependent on the presence of PR. Advanced breast cancer is associated with a hypercoagulable state. Progesterone has been shown to enhance the coagulation cascade proteins TF and PAR1 promoting cancer cells angiogenesis, coagulation, migration and invasion. This may be another mechanism by which progesterone may contribute to the increase in breast cancer incidence in women using continuous combined HRT.
7 RANK/RANKL and Progesterone
RANKL—receptor activator of the NF-kβ ligand is highly expressed in human breast cancer cells. RANK and its ligand RANKL are expressed in preinvasive mammary intraepithelial neoplasia and invasive carcinoma of the human breast. The dividing epithelial cells do not contain ER or PR, but are controlled by adjacent resting cells containing sex steroid receptors which secrete various growth factors, of which RANKL emerges as a key paracrine mediator of the progesterone mitogenic signal. It has been shown that progesterone-knock-out (PRKO) mice mammary epithelial cells, when mixed with wild-type (WT) cells, contribute to alveolar and ductal side branching in the pregnant state. This suggests a paracrine factor transmitted from the wild-type breast cells and received by the knock-out cells causing them to proliferate. This paracrine factor was found to be RANKL [36].
Mammary RANKL is induced by exogenous progesterone. In the proliferative phase of pregnancy (in which progesterone is at its peak action driving mammary epithelium expansion and morphogenesis), RANKL is markedly expressed. RANKL expression is confined to ER+/PR+ transmitters’ cells [37]. Consequently RANKL may act as the direct link between breast cells via progesterone. Finally, evidence that RANKL has a mediator role in mammary progesterone signaling, came from a study where PRKO mammary epithelial cells were transplanted into the mammary fat pad of WT mice. RANKL triggered mammary side-branching and alveolar budding in the PRKO transplant within the pregnant WT host [38]. It has been demonstrated that the RANKL transduction axis is actually essential for progesterone promotion of mammary tumorigenesis [39, 40]. In these studies MPA (medroxyprogesterone acetate), the progestin used in the WHI study, significantly increased RANKL expression in the ER+/PR+ cell population, in mammary normal epithelium as well as in premalignant and malignant cells. Therefore it is evident that progesterone (as well as MPA) relies on RANKL as a paracrine mediator for its proliferative effects. RANKL also enables the mammary epithelium to evade premature apoptosis.
8 Progesterone and E-Cadherin
E-Cadherin is an epithelial adhesion protein, which is an important, if not the major, component of the tight junctions between mammary epithelial cells. It has been shown that decrease, or loss, of the E-Cadherin protein is associated with tumor cell metastasis and invasiveness, and a poorer prognosis in breast cancer patients [41]. E-cadherin protein is highly expressed in normal epithelial cells adjacent to the breast tumors. In an experimental rat model, treatment with E + the R5020 (promegestrone) decreased the levels of E-cadherin precursor and mature E-cadherin protein [42]. This effect was abolished by the progesterone antagonist mifepristone (RU486), implying that the effect is due to the progestin component. In this rat model E + P treatment, as compared with E alone resulted in invasive mammary cancers accompanied by decreased E-cadherin levels and expansion of cells with a basal/myoepithelial phenotype. Similar findings have been observed in invasive primary human breast cancers compared to matched carcinoma in situ. While estrogen alone is sufficient to induce luminal noninvasive tumors, progesterone is required for the expansion of basal-myoepithelial tumor cells that frequently express progesterone receptor B. Progesterone promotes expansion of the more invasive basal/myoepithelial cells via direct activation of progesterone receptor B. It is important to note that only progesterone receptor B mediates the effect of progestins on E-cadherin. The ratio of progesterone receptors A/B is almost equal in normal breast tissue. But this ratio is completely altered, in favor of more B receptor in cancerous breast cells.
Loss of E-cadherin is a hallmark of the invasive behavior of luminal breast cancer cell lines. In vitro studies have found that treatment with E+P leads to complete loss of E-cadherin in 77 % of the tumors in the rat model. The data now indicate that Progesterone acting through progesterone receptor B regulates E-cadherin protein expression. Progestins, therefore specifically contributes to the aggressiveness and invasion of breast cancer cells.
9 Conclusion
Clinical studies, such as the WHI, Million women study and others have accelerated the research to find “evidence” to prove, or disprove, the clinical findings. It soon became apparent that progesterone, the “insignificant hormone”partner of estrogen in hormone replacement therapy plays an important and complex role in mammary carcinogenesis. Progesterone works synergistically with estrogen on the breast, inducing alveolar proliferation. Progesterone has always been considered as an anti-proliferative hormone due to its action on the endometrium, opposing the proliferative effect of estrogen. Hence progestogens were introduced into hormone replacement regimens: to counteract estrogen induced endometrial proliferation. Many laboratories throughout the world are trying to elucidate progesterone dependent mechanisms, in order to clear controversial issues reported in clinical studies. However, thus far it is clear that there is much more to progestogens and their widespread actions on genes, receptors and tissues causing, promoting and inducing breast cancer. In view of the new information gathered so far, new well designed prospective clinical studies are now needed.
References
1.
Brown JB. Types of ovarian activity in women and their significance. Hum Reprod Update. 2011;17(2):141–58.PubMedCentralCrossRefPubMed
2.
Ringa V, Fritel X, et al. Association between premenstrual progesterone and postmenopausal hormone therapy in the GAZEL cohort. Maturitas. 2007;58:216–25.CrossRefPubMed
3.
Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293(23):1167–70.CrossRefPubMed
4.
Chelbowski RT, Hendrix SL, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women;- The women health initiative randomized trial. JAMA. 2003;289:3242–53.CrossRef
5.
Anderson GL, Chlebowski RT, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy; extended follow up of the women’s health initiative randomized placebo-controlled trial. Lancet Oncol. 2012;13:476–86.PubMedCentralCrossRefPubMed
6.
Jick SS, Hagberg KW, et al. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet Gynecol. 2009;113:74–80.CrossRefPubMed
7.
Collins JA, Blake JM. Breast cancer risk with postmenopausal hormone treatment. Reprod Update. 2006;121:331.
8.
Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012;1041:517–27.CrossRef
9.
Fournier A, Berrino F, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–54.CrossRefPubMed
10.
Gaham JD, Yager M, et al. Altered progesterone receptor isoforms expression remodels progestins responsiveness of breast cancer cells. Mol Endocrinol. 2005;19:2713–35.CrossRef
11.
Khan JA, Bellance C, et al. Differential regulation of breast cancer-associated genes by progesterone receptors isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One. 2012;7:45993.CrossRef
12.
McKenna NJ, Lanz RB, et al. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999;20:321–44.PubMed
13.
Guiochon-Mantel A, Delabre K, et al. Nuclear localization signals also mediate the outward movement of proteins from the nucleus. Proc Natl Acad Sci U S A. 1994;91:7179–83.PubMedCentralCrossRefPubMed
14.
Boonyaratanakornkit V, Bi Y, et al. The role and mechanism of progesterone receptors activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids. 2008;73:922–8.CrossRefPubMed
15.
Mote PA, Bartow S, et al. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72:163–72.CrossRefPubMed
16.
Clemm DI, Sherma L, et al. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by phosphoserine site-specific monoclonal antibody. Mol Endocrinol. 2000;14:52–65.CrossRefPubMed
17.
Hagan CR, Lange CA. Molecular determinants of context-dependent progesterone receptor action in breast cancer-minireview. BMC Med. 2014;12:32.PubMedCentralCrossRefPubMed
18.
Pasqualini JR. Breast cancer and steroid metabolizing enzymes: the role of progesterone. Maturitas. 2009;655:s17–21.CrossRef
19.
Perou CM, Sorlie T, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–52.CrossRefPubMed
20.
Al-Hajj M, Wicha MS, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.PubMedCentralCrossRefPubMed
21.
Dontu G, El-Ashry D, et al. Breast cancer/progenitor cells and estrogen receptor. Trends Endocrinol Metab. 2004;15:193–7.CrossRefPubMed
22.
Clarke RB. Ovarian steroids and the human breast, regulation of stem cells and cell proliferation. Maturitas. 2006;54:327–34.CrossRefPubMed
23.
Horwitz KB, Dye WW, et al. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA. 2008;105:5774–9.PubMedCentralCrossRefPubMed
24.
Horwitz HB, Sartorius CA. Progestins in hormone replacement therapies. Reactive cancer stem cells in women with pre-existing breast cancer-A hypothesis. J Clin Endocr Metab. 2008;93(9):3295–8.PubMedCentralCrossRefPubMed
25.
Stanczyk FZ, Hapgood JP, et al. Progestogens used in postmenopausal hormone therapy. Differences in their pharmacological properties, intracellular actions and clinical effect. Endocr Rev. 2013;34(2):171–208.PubMedCentralCrossRefPubMed
26.
Kuhl H, Schneider HPG. Progesterone- a promoter or inhibitor of breast cancer. Climacteric. 2013;16 suppl 1:54–68.CrossRefPubMed
27.
Wiebe JP, Beausoleil M, et al. Opposing actions of progesterone metabolites 5α-dihydroprogesterone (5αP) and 3α- Bcl-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol. 2010;118:125–32.CrossRefPubMed
28.
Wiebe JP. Progesterone metabolites in breast cancer. Endocr Relat Canc. 2006;13:717–38.CrossRef
29.
Kato S, Pinto M, et al. Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocr Metab. 2005;90:1181–8.CrossRefPubMed
30.
Polland TD, Borisy GG. Cellular motility driven by assembly and disassembly of filaments. Cell. 2003;112(4):453–60.CrossRef
31.
Fu XD, Giretti MS, et al. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cell migration and invasion. BMC Cancer. 2008;8:166. 1–14.PubMedCentralCrossRefPubMed
32.
Critchley DR. Focal adhesions- the cytoskeletal connection. Curr Opin Cell Biol. 2000;12:133–9.CrossRefPubMed
33.
Ossovskaya VS, Bunnett NW. Protease-activated receptors; contribution to physiology and disease. Physiol Rev. 2004;84:579–621.CrossRefPubMed
34.
Hague S, Oehler MK, et al. Protease activated receptor-1 is down regulated by levonorgestrel in endometrial stromal cells. Angiogenesis. 2002;5:93–8.CrossRefPubMed
35.
Even-Ram S, Uziely B, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4:909–14.CrossRefPubMed
36.
Diaz J, Aranda E, et al. Progesterone promotes focal adhesion formation and migration in breast cancer cells through induction of protease-activated receptor -1. J Endocrin. 2012;214:165–75.CrossRef
37.
Fernandez-Valdivia R, Lydon JP. From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol. 2012;357(1–2):91–100.PubMedCentralCrossRefPubMed
38.
Fernandez-Valdivia R, Mukherjee A, et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol. 2009;328:127–39.CrossRefPubMed
39.
Beleut M, Rajaram RD, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A. 2010;107:2989–94.PubMedCentralCrossRefPubMed
40.
Gonzalez-Suarez E, Jacob AP, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468:103–7.CrossRefPubMed
41.
Schramek D, Leibbrandt A, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468:98–102.PubMedCentralCrossRefPubMed
42.
Siitonen SM, Kononen JT, et al. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 1996;105:394–402.PubMed